Key findings include specific targeting of EpCAM in MCF-7 breast cancer cells, achieved through conjugation of anti-EpCAM onto MONA, rapid apoptosis of MCF-7 cells facilitated by light-driven molecular, doxorubicin (DOX) delivery, utilizing a highly focused photothermal gradient generated by the asymmetric AuNC, and monitoring of apoptotic events, particularly cytochrome c activity in response to DOX releases by measuring plasmonic energy resonance transfer (PRET) between the AuNC and cytochrome c molecules. Here, EPCAM is linked to breast cancer.